Neural Circuit Effects of Ketamine in Depression
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
Age: 18 - 65 years
Gender: All
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Ketamine is a NMDA-receptor antagonist that promotes synapse formation and has been shown to
rapidly improve symptoms in depression. Even a single dose of ketamine has been shown to
improve depression and cognition with short-term memory, inhibitory control, cogniti...
Age: 50 - 90 years
Gender: All
Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression
Patients with major depressive disorder (MDD) exhibit increased levels of rumination (i.e.
repetitive thinking and focus on negative mood states) which have been found to increase the
risk of depressive relapse. The ability to reduce rumination levels among these pa...
Age: 18 - 65 years
Gender: All
DBS for TRD With the Medtronic Percept PC
Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resi...
Age: 25 - 70 years
Gender: All
Invasive Decoding and Stimulation of Altered Reward Computations in Depression
Novel invasive neurostimulation stimulation strategies through neurosurgical interventions are emerging as a promising therapeutical strategy for major depressive disorder. These have been applied mostly to the anterior cingulate cortex, but other limbic brain regions h...
Age: 18 - 80 years
Gender: All
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin
17A (IL-17A), in patients with treatment-resistant depression (TRD).
Age: 18 - 65 years
Gender: All
XEN1101 for Major Depressive Disorder
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a
novel treatment target for mood disorders through the administration of the KCNQ-selective
channel opener XEN1101 (Xenon Pharmaceuticals).
Age: 18 - 65 years
Gender: All
Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression
Previous research has shown that modulation of a brain region in rodents, the ventral
tegmental area (VTA), improves depressive symptoms. Human research has also shown that VTA
self-modulation using 'biofeedback' is feasible and successful in healthy volunteers. Thi...
Age: 18 - 65 years
Gender: All
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to
a no stimulation control in producing a reduction in baseline depressive symptom severity,
based on multiple depression scale assessment tools at 12 months from randomizati...
Age: 18 years - 66+
Gender: All